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The underlying molecular genetic basis of combined
hyperlipidemia, the most common atherogenic lipid
disorder, is poorly characterized. Rare, nonconser-
vativemutations in theWnt coreceptor, LRP6, under-
lie autosomal dominant atherosclerosis, combined
hyperlipidemia, and fatty liver disease. Mice with
LRP6R611C mutation similarly developed elevated
plasma LDL and TG levels and fatty liver. Further
investigation showed that LRP6R611C mutation trig-
gers hepatic de novo lipogenesis, lipid and choles-
terol biosynthesis, and apoB secretion by an
Sp1-dependent activation of IGF1, AKT, and both
mTORC1 and mTORC2. These pathways were
normalized after in vitro treatment of primary hepato-
cytes from LRP6R611C mice with either the IGF1R
antagonist PPP, rapamycin, or rmWnt3a. Strikingly,
in vivo administration of rmWnt3a to LRP6R611C
mice normalized the altered expression of enzymes
of DNL and cholesterol biosynthesis, and restored
plasma TG and LDL levels to normal. These findings
identify Wnt signaling as a regulator of plasma lipids
and a target for treatment of hyperlipidemia.
INTRODUCTION
Familial combined hyperlipidemia (CHL), featuring elevated
levels of plasma triglycerides (TGs) and low-density lipoprotein
(LDL) cholesterol (C), is themost common form of hyperlipidemia
found in the general population. Despite 40 years of investiga-
tion, no single gene has been clearly linked to this disorder,
and its underlying molecular mechanisms remain poorly under-
stood. We identified rare nonconservative loss of function muta-
tions in the gene encoding Wnt coreceptor LRP6 (OMIM,
ADCAD2), which underlie autosomal dominant, early onset cor-
onary artery disease (CAD), and metabolic syndrome traits,
including elevated plasma TG and LDL-C levels, diabetes, oste-Cell Moporosis, and hypertension (Mani et al., 2007; Singh et al.,
2013b). These findings underscore the emerging evidence impli-
cating effects of altered Wnt signaling on plasma lipids. Low
serum levels of Wnt1 are associated with elevated TG and
LDL-C in patients with premature CAD (Goliasch et al., 2012).
Common genetic variants in genes encoding TCF7L2 are asso-
ciated with elevated plasma TG in kindreds with familial com-
bined hyperlipidemia (Delgado-Lista et al., 2011; Huertas-Vaz-
quez et al., 2008), while genetic variants in LRP6 have been
associated with risk for elevated LDL-C (Tomaszewski et al.,
2009) in the general population. The functional characterization
of the common genetic variants is hindered by their inherent
small magnitude of effect on the trait. In contrast, the large
effects imparted by the nonconservative LRP6 mutations have
allowed detailed studies of their effects both in vitro and in
primary human cells. The studies of macrophages and skin
fibroblasts of the LRP6R611C mutation carriers have shown
that elevated plasma LDL-C is, partially, the result of impaired
receptor-mediated uptake of LDL (Liu et al., 2008; Ye et al.,
2012). The contribution of LRP6 to LDL clearance was later
confirmed by a genome-wide targeted RNAi screening of
cholesterol-regulating genes (Bartz et al., 2009). LRP6 primarily
facilitates LDL receptor (LDLR)-dependent LDL clearance in
most human cells (Ye et al., 2012). LRP6 forms a complex with
LDLR, clathrin, and autosomal recessive hypercholesterolemia
protein and is required for clathrin-mediated vesicular LDL
uptake (Ye et al., 2012). These functions are impaired in
hematopoietic cells and skin fibroblasts of the LRP6R611C muta-
tion carriers, resulting in 15%–20% lower LDL clearance
compared to wild-type (WT) cells. The same magnitude of
reduction in LDL uptake occurs when LRP6 is knocked down
by RNA interference. This modest reduction in LDL clearance,
however, does not explain the severe degree of hyperlipidemia
in LRP6R611C mutation carriers, raising the possibility that
increased synthesis and secretion of apolipoprotein B (apoB)-
containing lipoproteins constitute major disease mechanisms.
To address this question, we generated a mouse model of
LRP6R611C mutation (Lrp6mut/+) by modifying the endogenous
mouse LRP6 through homologous recombination. To assess
the LDLR-independent role of LRP6 in the hyperlipidemia
present in this mouse, Lrp6mut/mut mice were crossbred ontoetabolism 19, 209–220, February 4, 2014 ª2014 Elsevier Inc. 209
Figure 1. Plasma Lipid Profiles in Lrp6mut/mut and Ldlr–/–/Lrp6mut/mut Mice
(A–C) Higher-plasma TG, total C, and LDL-C levels in Lrp6mut/mut mice on chow diet and (F–H) HCD compared to WT mice on same diets. (K–M) Higher-plasma
TG, total C, and LDL-C levels in Ldlr//Lrp6mut/mutmice on HCD compared to Ldlr/mice on same diet. (D and E) Lipoprotein separation by FPLC in Lrp6mut/mut
mice on chow diet and (I and J) HCD diet show higher TG content of VLDL and higher TC content of IDL/LDL in Lrp6mut/mut compared toWTmice. *p < 0.05; **p <
0.01; ***p < 0.001. WT, wild-type; HCD, high cholesterol diet; TG, triglycerides; Total C, total cholesterol; LDL-C, LDL cholesterol; FPLC, fast protein liquid
chromatography. Error bars represent SD. See also Figure S1.
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and their regulation by Wnt/LRP6 pathways were examined in
Lrp6mut/mut and Ldlr/Lrp6mut/mut mice.
RESULTS
Lrp6mut/mutMice Exhibit Elevated Plasma LDL-C and TG
Mice with LRP6R611C (Lrp6mut/+) on B57BL/6 background were
generated by manipulating mouse endogenous LRP6 through
homologous recombination (see Experimental Procedures).
Three-month-old heterozygote Lrp6mut/+ mice on chow diet
have significantly higher plasma TG, total C, and LDL-C
compared to WT mice (see Figure S1 available online). These
levels were intermediate between WT and homozygous mutants
(Figure S1). Plasma lipids were significantly higher in homozy-
gote Lrp6mut/mut mice compared to WT (Figures 1A–1C); homo-
zygous mice were then used for further experimentation. There
was no significant difference in free fatty acid levels between
the two strains (data not shown). Lipid profiling of FPLC-sepa-
rated lipoprotein fractions showed that, as expected, the
increased TG in Lrp6mut/mut mice was predominantly associated
with VLDL particles (Figure 1D). FPLC also showed higher non-
HDL-C (IDL/LDL) in the mutant versus WT mice (Figure 1E).
Lrp6mut/mut mice on 6 months of high-cholesterol/high-fat diet
(HCD) (40% fat, 1.25% cholesterol, 0.5% cholic acid) had about
2-fold increase in plasma TG (Figure 1F) and about 3-fold in-
crease in total C (Figure 1G) and LDL-C (Figure 1H) compared
to WT littermates. FPLC-separated lipoprotein similarly showed
higher TG in the VLDL fraction and higher cholesterol in the non-
HDL-C fraction in Lrp6mut/mut versusWTmice on HCD (Figures 1I
and 1J). We had previously shown that LRP6 regulates LDLR-
mediated vesicular uptake of LDL. To examine the unique role
of LRP6 in lipoprotein assembly and secretion, Lrp6mut/mut
mice were crossbred onto Ldlr/ mice to generate Ldlr//
Lrp6mut/mut mice. Introducing the LRP6R611C allele into Ldlr/210 Cell Metabolism 19, 209–220, February 4, 2014 ª2014 Elsevier Inmice background resulted in significant increase in plasma TG,
total C, and LDL-C (Figures 1K–1M) in 9-month-old mice on
HCD compared to Ldlr/ mice. Since the effect of LRP6R611C
allele on LDL binding and clearance is relatively small (Liu
et al., 2008; Ye et al., 2012) (Figures 2A and 2B), the major differ-
ences in plasma lipoproteins and lipids cannot be explained by
decreased clearance and must be, therefore, the result of
increased production of VLDL (see below).
Lrp6mut/mut Mice Develop Fatty Liver Disease
CHL is associated with nonalcoholic fatty liver disease (An-
gulo, 2002). Both 6-month-old WT and Lrp6mut/mut mice on HCD
for 3 months developed fatty liver, but the fat content in
Lrp6mut/mut mice was significantly higher (Figure 3A), which was
associated with gross enlargement of the liver and elevated
plasma levels of aspartate aminotransferase andbilirubin (Figures
S2A and S2D). Accordingly, the neutral lipid storage assayed by
Nile red staining was significantly greater in primary hepatocytes
of Lrp6mut/mut versus WT mice on HCD (Figure 3B). Total hepatic
TG and cholesterol ester (CE) contents were also significantly
higher in Lrp6mut/mut versusWTmice (Figures 3C and 3D). No dif-
ference in b-oxidation was seen between primary hepatocytes
fromWTandLrp6mut/mutmice (Figure 3E). Theexaminationof fatty
acid composition in the liver of Lrp6mut/mut mice showed greater
18:1n9 fattyacidcontent inLrp6mut/mutcompared toWTmice (Fig-
ure S3A). This findingwas consistentwith increasedexpressionof
SCD1, aswill be shown.Nodifferencewas found in fatty acid con-
tents of WAT between Lrp6mut/mut and WT mice (Figure S3B).
Increased TG/VLDL Synthesis and Secretion
in Lrp6mut/mut Mice Are Associated with Enhanced
Expression of Lipogenic Enzymes
We measured in vivo VLDL clearance in mice on chow diet by
intravenous injection of 125I-VLDL. The radioactivity remaining
in apoB, the marker of VLDL particles, at 2, 30, 60, 120, andc.
Figure 2. Binding and Uptake of Lipoproteins and Fatty Aicds in Lrp6mut/mut and Ldlr–/–/Lrp6mut/mut Mice
(A) Binding and (B) uptake of 125I-LDL and (C) uptake of 125I-VLDL in Lrp6mut/mut and wild-type (WT) mice hepatocytes. (D) 14C-acetate, (E) 14C-palmitate, and (F)
14C-oleate uptake by the hepatocytes of Lrp6mut/mut compared toWTmice. (G) Greater 14C-acetate (H) palmitate and (I) oleate uptake by hepatocytes of Ldlr//
Lrp6mut/mut compared to Ldlr/ mice. *p < 0.05; **p < 0.01; ***p < 0.001. Error bars represent SD.
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in Lrp6mut/mut and WT mice. The experiment showed no differ-
ences in VLDL clearance between the two groups (Figure 4A).
Similarly, there was no change in VLDL uptake by primary hepa-
tocytes of Ldlr//Lrp6mut/mut versus Ldlr/mice (Figure 2C). To
assess VLDL-apoB secretion, 6 hr fasted mice were injected i.p.
35S-methionine and P407, a polyoxyethylene copolymer that
blocks LPL-mediated lipolysis of VLDL in plasma. VLDL-apoB
secretion, assayed by in vivo measurement of the appearance
of newly secreted 35S-methionine-labeled apoB100 radioac-
tivity, was significantly greater in Lrp6mut/mut than in WT mice
(Figure 4B). We next examined the TG secretion in 8- to 10-
week-old Lrp6mut/mut andWTmice. Plasma TG levels rose imme-
diately after i.p. P407 injection in both WT and Lrp6mut/mut mice
but began to diverge after 1 hr and remained significantly higher
at 24 hr in Lrp6mut/mut than inWTmice (Figure 4C). The combined
apoB100 and TG results indicate significantly greater hepatic
secretion of VLDL particles in Lrp6mut/mut compared to WT
mice. To assess de novo lipogenesis (DNL) and TG synthesis,
primary hepatocytes from Lrp6mut/mut and WT mice were incu-
bated with 14C-acetate, 14C-plamitate, and 14C-oleate. TG was
isolated by thin-layer chromatography (TLC), and the 14C incor-
porations were measured. The results showed 7-fold increase in
incorporation of labeled acetate and greater than 60% increase
of labeled palmitate and oleate into TG in Lrp6mut/mut mice
compared to WT littermates (Figures 4D–4F). Similarly, there
was increased incorporation of all three labels into TG in primaryCell Mhepatocytes of Ldlr//Lrp6mut/mut mice compared to Ldlr/
mice (Figures 4G–4I). Taken together, these findings indicated
increased DNL and TG synthesis associated with increased
VLDL secretion in HCD-fed mice with the R611C allele.
To explore the mechanisms that underlie enhanced DNL, TG
synthesis, and VLDL secretion, mRNA and protein expression
levels of MTP, apoB, and the key hepatic enzymes of DNL were
compared between Lrp6mut/mut and WT mice on both chow diet
and HCD. Protein and mRNA levels of ACC1, FASN, ELOVL6,
SCD1, DGAT1, GPAT1, MTP, and apoB were all higher in
Lrp6mut/mut liver than in WT littermates (Figures 4J and 4K; data
shown for chow diet). These proteins are regulated by SREBP1
and LXRa (Basciano et al., 2009; Darimont et al., 2006; Wang
et al., 2004). Accordingly, the expression levels of the mature
form of SREBP1 and the level of LXRa in nuclear extracts were
considerably higher in Lrp6mut/mut liver compared to WT litter-
mates (Figure 4J). Similar changes were observed in mice with
Ldlr/ background (Figure S4). In concordancewith this, 14C-ac-
etate, palmitate, and oleate uptake by Lrp6mut/mutmouse hepato-
cytes was significantly increased compared to WT mice (Figures
2D–2F). The same increase in uptake of these substrates was
seen inhepatocytes fromLdlr//Lrp6mut/mutmice (Figures2G–2I).
Lrp6mut/mut Allele Triggers Hepatic Cholesterol
Biosynthesis
Ldlr//Lrp6mut/mut mice had significantly higher plasma LDL-C
levels compared to Ldlr/ mice. Since the effect of LRP6R611Cetabolism 19, 209–220, February 4, 2014 ª2014 Elsevier Inc. 211
Figure 3. Fatty Liver in Lrp6mut/mut Mice
(A) Oil red O staining in 6-month-old mice on HCD shows greater amounts of hepatic fat in Lrp6mut/mut compared to WT mice. Scale bars, 100 mm. (B) Similarly,
there is greater neutral lipid, assayed by Nile red staining, (C) and greater TG and (D) cholesterol ester (CE) content, measured by enzymatic assays in Lrp6mut/mut
liver compared toWTmice. (E) No difference in fatty acid oxidation, assayed by 14C-CO2, was found between Lrp6
mut/mut andWTmice. *p < 0.05; **p < 0.01. WT,
wild-type; HCD, high-cholesterol diet; TG, triglycerides; CE, cholesterol ester. Error bars represent SD. See also Figures S2 and S3.
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ence could be exclusively explained by enhanced production
of plasma LDL. Elevated LDL-C was from increased secretion
of large VLDL particles (Figure S5). We compared hepatic C
biosynthesis in primary hepatocytes of Ldlr//Lrp6mut/mut
versus Ldlr/ mice by measuring incorporation of 14C-acetate
and 14C-oleate into free C (FC) and C ester (CE). 14C incorpora-
tions into FC and CE were higher in mice Ldlr//Lrp6mut/mut
versus Ldlr/ mice (Figures 5A and 5B). These findings were
consistent with increased hepatic mRNA and protein expression
of HMGCR in Ldlr//Lrp6mut/mut versus Ldlr/mice (Figures 5C
and 5D). In line with these results, the mature form of SREBP2,
the key regulatory enzyme of C biosynthesis, was significantly
higher in nuclear extracts from Ldlr//Lrp6mut/mut compared to
Ldlr/ mice (Figure 5D). SREBP1 and SREBP2 are retained in
the ER by Insig1 and Insig2 (Yabe et al., 2002; Yang et al.,
2002) and upon various conditions, including activation by AKT
(Du et al., 2006), are transported with SCAP to Golgi for proteo-
lytic cleavage (Hua et al., 1996) and subsequent translocation to
nucleus. In line with increased expression of mature form of
SREBPs and enhanced C biosynthesis, the expression levels
of SCAP1 were increased and those of Insig1 and Insig2 were
reduced in Lrp6mut/mut mice liver compared to WT littermates
(Figure 5D). Genome-wide pattern of TCF7L2 chromatin occu-
pancy has shown that TCF7L2 binds the 30 transcription start
site of Insig1 (Hatzis et al., 2008). Wnt is upstream of TCF7L2,
and its impaired activity in Lrp6mut/mut is consistent with the212 Cell Metabolism 19, 209–220, February 4, 2014 ª2014 Elsevier Indiminished expression of Insig1 mRNA and protein. Higher he-
patic expression levels of SCAP1 mRNA and protein in Ldlr//
Lrp6mut/mut versus Ldlr/ mice suggests inverse regulation of
SCAP1 by Wnt/LRP6. This effect of LRP6 has not been previ-
ously described, and its underlying mechanisms are still unclear.
Activation of mTOR and IGF1 Pathways in Lrp6mut/mut
Mice Liver
Plasma lipids levels in humans are influenced by nutrients. The
nutrient-sensing kinase mTOR is the core component of multi-
protein complexes mTORC1 and mTORC2, which regulate
metabolism and lipid homeostasis by phosphorylating several
ribosomal proteins, including S6, S6K, and 4E-BP1 (Laplante
and Sabatini, 2009). mTORC1 is activated by PI3K/AKT and
mTORC2 (Yecies et al., 2011), directly stimulates SREBP1 and
SREBP2, and induces the expression of various lipogenic en-
zymes (Dalle Pezze et al., 2012; Hagiwara et al., 2012; Yuan
et al., 2012). Phosphorylations of AKT (S473), S6K, S6, and 4E-
BP1 were all significantly greater in Lrp6mut/mut mice liver
compared to WT mice, both on chow diet (Figure 6A) and on
HCD (data not shown).
In the liver, the PI3K/AKT pathway is primarily activated by in-
sulin and IGF1 (Hagiwara et al., 2012). Lrp6mut/mut mice have
normal baseline insulin and glucose levels but have an impaired
response to intraperitoneal insulin administration (IPITT) (Fig-
ure 6B). Consistent with the plasma findings, dissection of insulin
signaling revealed reduced tyrosine phosphorylation of IRS1 inc.
Figure 4. TG Synthesis and apoB Secretion
(A) Hepatic VLDL clearance was identical in Lrp6mut/mut and WT mice. (B) apoB secretion and (C) TG synthesis were higher in Lrp6mut/mut compared to WT mice.
Incorporation of 14C-acetate, 14C-palmitate, and 14C-oleate into TG by TLC were greater in (D–F) Lrp6mut/mut and (G–I) Ldlr//Lrp6mut/mut mice hepatocytes
compared to WT and Ldlr/ mice, respectively. (J) Protein and (K) mRNA expression of the hepatic enzymes of DNL, lipid synthesis and VLDL secretion and
nuclear LXRa and SREBP1were significantly higher in Lrp6mut/mut compared toWTmice. The relative intensities by densitometry are shown. *p < 0.05; **p < 0.01;
***p < 0.001. WT, wild-type; TG, triglycerides; VLDL, very low density lipoprotein; DNL, de novo lipogenesis; TLC, thin layer chromatography. Error bars represent
SD. See also Figure S4.
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phosphorylation (S473) in response to insulin was paradoxically
higher in Lrp6mut/mut compared to WT mice (same figure). ThisCell Mfinding led to examination of IGF1/AKT pathway. Hepatic
IGF1R protein and mRNA and plasma IGF1 protein were all ex-
pressed at significantly greater levels in Lrp6mut/mut comparedetabolism 19, 209–220, February 4, 2014 ª2014 Elsevier Inc. 213
Figure 5. Cholesterol Biosynthesis in Ldlr–/– and Ldlr–/–/Lrp6mut/mut Mice
Incorporation of (A) 14C-acetate into FC and (B) 14C-oleate into CE by TLC were much greater in primary hepatocytes from Ldlr//Lrp6mut/mut compared to
Ldlr/ mice. (C) mRNA and (D) protein expression levels of the key regulatory enzymes/proteins of cholesterol biosynthesis were significantly higher in Ldlr//
Lrp6mut/mut compared to Ldlr/mice. The relative intensities by densitometry are shown. *p < 0.05; **p < 0.01; ***p < 0.001. FC, free cholesterol; CE, cholesterol
ester; TLC, thin-layer chromatography. Error bars represent SD. See also Figure S5.
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Wnt Regulation of Plasma Lipidsto WT mouse (Figures 6C–6E). IRS-1-independent AKT activa-
tion has been previously described in IRS-1-deficient mice (Araki
et al., 1994). This finding suggests that impaired Wnt signaling
(assayed by LRP6 and b-catenin phosphorylation, Figure 6C) en-
hances AKT phosphorylation despite hepatic insulin resistance,
primarily through increased IGF1/IGF1R expression.
We have previously shown that IGF1R is ubiquitinated by
LRP6 (Singh et al., 2013a). Impaired ubiquitination and increased
sumoylation of IGF1R by LRP6R611C result in increased IGF1R
expression, which contributes to mTOR activation in response
to insulin. LRP6 regulation of IGF1 was an important finding
that required further exploration. Canonical Wnt upregulates
Sp5, which suppresses the transcriptional activities of transcrip-
tion factor Sp1 (Fujimura et al., 2007). IGF1 is transcriptionally
regulated by Sp1 (Li et al., 2003; Zhu et al., 2000), hence its
expression is likely diminished by Wnts activation. In contrast,
the anticipation is that the LRP6R611Cmutation results in reduced
Sp5 expression and enhanced Sp1-dependent transcription of
IGF1. As predicted, the expression levels of Sp5 were markedly
reduced in Lrp6mut/mut mice liver compared to WT mice (Figures
6C and 6D). The expression levels of Sp1 protein and mRNA
were significantly higher in Lrp6mut/mut mice hepatocytes versus
WT mice, but the relatively greater increase in protein level
implied both transcriptional and posttranscriptional regulation
by Wnt/LRP6 (same figure). We explored this possibility in
HepG2 cells by sh-RNA-mediated knockdown of LRP6. LRP6
silencing led to reduced Sp5 and increased Sp1 protein (Fig-
ure 6F) and mRNA (Figure 6G) expressions, associated with214 Cell Metabolism 19, 209–220, February 4, 2014 ª2014 Elsevier Inincreased expressions levels of lipogenic enzymes, SREBP1
and LXRa. Furthermore, lentiviral knockdown of Sp1 in primary
mice hepatocytes resulted in significant decrease in protein
levels of IGF1 and phosphorylation of AKT (AKT-pT308 and
AKT-pS473) (Figure 6H). Consistent with these findings, treat-
ment of primary mouse hepatocytes with the IGF1R inhibitor
PPP abrogated AKT-dependent activation of mTOR pathway
and reduced the expression of lipogenic enzymes (Figures S6A
and S6B). These findings imply that the LRP6R611C loss-of-func-
tion mutation increases hepatic IGF1 signaling and triggers the
expression of lipogenic enzymes via the AKT/mTOR-dependent
pathways.
Reduction of the Hepatic Lipogenic Enzymes with
Rapamycin and Wnt3a Activation
The expression and activities of enzymes regulating DNL, TG
synthesis, and C synthesis are dramatically reduced when pri-
mary mouse hepatocytes are treated either with the mTOR
antagonist rapamycin (Figure 7A) or with recombinant mouse
Wnt3a (rmWnt3a) (Figure 7B). Treatment with rmWnt3a for
72 hr was also associated with normalization of hepatocyte
neutral lipid (Figure 7B). Given the positive response to in vitro
rmWnt3a, we administered systemic rmWnt3a to Lrp6mut/mut
mice (i.p. 25 mg/kg) every other day for 3 weeks. This resulted
in the reduction of plasma TG (Figure 7C), total C (Figure 7D),
and LDL-C (Figure 7E) in both WT and Lrp6mut/mut mice. These
changes were associated with significantly reduced expression
and/or activities of Sp1, IGF1, mTOR, ACC1, FASN, SCD1,c.
Figure 6. Activities of mTORC1, mTORC2, and IGF1 in Lrp6mut/mut Mice
(A) Western blot analysis demonstrating the greater activities of hepatic AKT/mTOR pathways in Lrp6mut/mut compared to WTmice. The ratios of phosphorylated
to total proteins by densitometry are shown. (B) Intraperitoneal insulin tolerance test (IPITT) and hepatic insulin signaling pathway show impaired insulin signaling
in Lrp6mut/mut compared to WT mice. The ratios of phosphorylated to total proteins by densitometry are shown. (C) Protein and (D) mRNA expression of the
hepatic IGF1 and IGF1R, the transcription factors Sp1 and Sp5, and (E) plasma IGF1 were are higher in Lrp6mut/mut compared to WT mice. (F) Protein and
(G) mRNA expression of transcription factors Sp5 and Sp1 and key enzymes of DNL are significantly altered after LRP6 silencing by shRNA in HepG2 cells.
(H) Protein expression levels of Sp1, IGF1, and phosphorylation of AKT (pT308 and pS473) were significantly reduced by Sp1 knockdown in primary hepatocytes
of WT and Lrp6mut/mut mice. *p < 0.05; **p < 0.01; ***p < 0.001. WT, wild-type; DNL, de novo lipogenesis. Error bars represent SD. See also Figure S6.
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forms of SREBP1 and SREBP2 (Figure 7F). To examine whether
rmWnt3a rescued the phenotype by signaling through the
mutant LRP6, we stimulated primary hepatocytes of the mutant
and WT mice with different doses of rmWnt3a. There was a shift
to the right in the dose response to rmWnt3a in the mutant hepa-
tocytes. However, higher doses of Wnt3a resulted in levels of
phosphorylation of the mutant LRP6 that were similar to levels
observed in WT receptor at lower doses (Figure S7). This in-
crease in LRP6 phosphorylation was associated with significant
reduction in expression of Sp1, IGF1, SREBP1, and SREBP2
(same figure). Taken together, these rescue studies implicateCell MWnt in regulation of mTOR/IGF1 pathways, DNL, lipid synthesis,
and secretion of apoB/VLDL.
DISCUSSION
Altered Wnt signaling is an emerging risk factor for dyslipidemia
by mechanisms that are not understood (Goliasch et al., 2012;
Huertas-Vazquez et al., 2008; Perez-Martinez et al., 2012). We
previously showed thatWnt coreceptor LRP6 regulates vesicular
LDL uptake, a finding that was confirmed by subsequent studies
(Bartz et al., 2009). Primary skin fibroblasts of LRP6R611C muta-
tion carriers exhibited 20% lower cellular LDL uptake comparedetabolism 19, 209–220, February 4, 2014 ª2014 Elsevier Inc. 215
Figure 7. Normalization of Hepatic mTOR by Rapamycin and Reduction of Plasma Lipids by rmWnt3a in Lrp6mut/mut Mice
(A) mTOR inhibitor rapamycin reduced the activation of mTORC1 and the expression of enzymes of DNL in Lrp6mut/mut versus WT mice. (B) Normalization of
hepatic neutral lipid, enzymes of DNL and C biosynthesis, and their regulators SREBP1 and SREBP2 by rmWnt3a in Lrp6mut/mut hepatocytes. (C) Normalization of
plasma TG (D) total C (E) LDL-C and (F) enzymes of DNL and C biosynthesis after administration of i.p. rmWnt3a to Lrp6mut/mut mice. (G) The schematic of Wnt/
LRP6 regulation of IGF1, IGF1R, mTOR pathways, DNL, TG synthesis, and C biosynthesis. *p < 0.05; **p < 0.01; ***p < 0.001. TG, triglycerides; C, cholesterol; rm,
recombinant mouse; WT, wild-type; DNL, de novo lipogenesis. Error bars represent SD. See also Figure S7.
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Wnt Regulation of Plasma Lipidsto fibroblasts from their unaffected relatives (Liu et al., 2008; Ye
et al., 2012). The severity of hypercholesterolemia in LRP6R611C
mutation carriers could not, however, be explained by the
modest degree reduction in LDL clearance; this prompted us
to generate transgenic mice with LRP6R611C mutation to
examine its effect on hepatic lipid metabolism and VLDL synthe-
sis and clearance. Here we show the important role of Wnt/LRP6
signaling in DNL, lipid synthesis, and apoB/VLDL secretion.
Lrp6mut/mut mice exhibited increased DNL, increased hepatic
TG and C synthesis, and increased secretion of both VLDL
apoB and TG compared to WT littermates. Higher hepatic DNL
was associated with development of fatty liver in Lrp6mut/mut
mice, a prominent feature of the metabolic syndrome (Angulo,
2002). These developments were coupled with increases in
levels of mRNA and protein of enzymes of DNL, TG, and C syn-
thesis, and their regulators SREBP1 and SREBP2, but not USF1,
the transcription factor associated with FCHL (data not shown).
AKT triggers SREBP1 and SREBP2 activation (Du et al., 2006)
and suppresses Insig2a gene expression (Yecies et al., 2011),
and there was increased hepatic AKT phosphorylation (S473),
associated with enhanced activities of mTORC2 in Lrp6mut/mut
mouse liver compared to WT mice. Further investigation re-
vealed that increased hepatic IGF1 and IGF1R expression and
action induce AKT/mTOR activation in Lrp6mut/mut mice. We
had previously shown that LRP6 triggers IGF1R ubiquitination,
while LRP6R611C allele promotes its stabilization (Singh et al.,
2013a). The effect of LRP6R611C allele on IGF1 transcription
was an important finding that we linked to impaired Wnt
signaling. Earlier studies have shown that Sp1 is a transcriptional
activator of IGF1 (Kaytor et al., 2001; Zhu et al., 2000). In this
study we show that Lrp6mut/mut mouse hepatocytes have signif-
icantly greater Sp1 expressions compared to WT mice. shRNA-
mediated silencing of LRP6 in primary hepatocytes increased
Sp1 expression, further confirming the critical role of Wnt/
LRP6 in regulation of this developmentally critical transcription
factor. Taken together, these findings suggest that Wnt signaling
tightly controls IGF1 expression and that its impaired function re-
sults in increased IGF1 and IGF1R expressions, leading to
enhancedmTORC2/AKT activation as summarized in Figure 7G.
Consistent with earlier findings (Yecies et al., 2011), enhanced
mTORC2-dependent AKT phosphorylation (S473) was associ-
ated with increased activation of mTORC1. The significance of
mTORC1 pathway in regulation of DNL in Lrp6mut/mut mice was
demonstrated by ex vivo treatment of Lrp6mut/mut liver cells
with rapamycin, which significantly reduced the activity of
mTORC1 and the expression of enzymes of DNL. As predicted,
no change in activity of mTORC2, assessed by AKT S473 phos-
phorylation, was observed.
Finally, our most striking finding was the normalization of
plasma LDL and TG by i.p. administration of rmWnt3a to
Lrp6mut/mut mice, which were associated with reduced expres-
sion of mature forms of SREBP1 and SREBP2 and enzymes of
DNL, TG, and C biosynthesis. In addition, Wnt3a treatment of
Lrp6mut/mut mouse hepatocytes resulted in significant reduction
of hepatic neutral lipid. These findings underscore the important
role of Wnt signaling in homeostasis of plasma lipids and hepatic
fat content and suggest that this pathway is a unique target
for development of novel therapeutics against hyperlipidemia
and FLD.Cell MThe rescue of hyperlipidemia trait with Wnt3a in a mouse with
mutated LRP6 and impaired Wnt signaling is likely caused by
improved interaction between ligand and its coreceptor. Study
of crystal structure of LRP6 had suggested that R611C mutation
impairs the salt bridge between R611 and E477 and weakens its
ligand binding ability (Cheng et al., 2011). Earlier studies by our
group (Mani et al., 2007) and others have shown that impaired
Wnt signaling caused by R611C mutation can be rescued by
higher doses of Wnt3a or by application of recombinant bigly-
can, an extracellular matrix protein that facilitates formation of
a complex between Wnt3a and LRP6 (Berendsen et al., 2011).
In the current study we show a shift to right in the dose response
to rmWnt3a in mutant hepatocytes. Strikingly, higher-dose
rmWnt3a normalized phosphorylation of the mutant LRP6 and
was associated with significant reduction in expression of Sp1,
IGF1, SREBP1, and SREBP2.
In summary, our study establishes a causal link between LRP6
mutation/altered Wnt signaling and combined hyperlipidemia
and elucidates the mechanisms by which Wnt signaling regu-
lates lipogenesis, lipid synthesis, and apoB secretion. Rescue
of the hyperlipidemia trait by Wnt3a in mice identifies the Wnt
signaling pathway as a potential target for development of novel
therapeutics against combined hyperlipidemia.
EXPERIMENTAL PROCEDURES
Generation of LRP6R611C Mice
Mice with LRP6R611C (Lrp6mut/+) mutation on B57BL/6 background were
generated by manipulating mouse endogenous LRP6 through homologous
recombination. Briefly, constructs containing mouse homologous DNA with
two nucleotide mutations at the positions 100443-5, which results in R593C
(mouse equivalent of human R611C mutation) substitution were generated
by the Vegalab LLC (Wilmington, DE). C57BL/6 ESCs were injected with the
constructs and targeted into the Balb/c blasts to generate chimeras. Chimeras
were crossed with B6mice, and genotype-positivemice were backcrossed for
eight generations prior to experimentation. Three-month-old heterozygous
Lrp6mut/+ mice had modest elevation of plasma TG. Lrp6mut/+mice were inter-
crossed to obtain homozygous offspring in the expectedMendelian ratios. The
viable offspring were genotyped by PCR (for primers, see Table S1). Homozy-
gote (Lrp6mut/mut) mice showed normal reproductive activities and had normal
size and growth. Southern blot analysis of a limited number of mice confirmed
the presence of LRP6R611C allele only (data not shown). The mutant LRP6
protein was expressed in most tissues, including liver, skeletal muscle, and
adipose tissue at normal levels. Homozygote Lrp6mut/mut were crossbred
onto Ldlr/ mice. The F1 progenies (Ldlr/+/Lrp6mut/+) were backcrossed
with Ldlr/ mice to obtain offspring that were heterozygous for the R611C
allele and LDLR deficient (Ldlr//Lrp6mut/+). Subsequent intercross of these
mice resulted in offspring that were homozygote for R611C allele and were
LDLR deficient in the expected Mendelian ratios.
Mice were fed ad libitum and at age 6–8 weeks were fed with either a normal
chow diet (9% kcal from fat) or a HCD for 3 months (40% kcal from fat, 1.25%
cholesterol, 0.5% cholic acid; Research Diet, D12109). Experiments were car-
ried out after overnight fasting. Each experiment was carried out in six to seven
mice. After mice were sacrificed, tissues were snap frozen and plasma was
separated, followed by storage at 80C for further analysis. All procedures
were approved by the Institutional Animal Care and Use Committee at Yale
University.
Antibodies
Antibodies to ACC1-pS79, ACC1, FASN, SCD1, tubulin, TBP, GAPDH, AKT-
pS473, AKT, GSK3b-pS21/9, GSK3b, TSC2-pT1462, TSC2, mTOR-pS2448,
mTOR, S6K-pT389, S6K, S6-pS240/244, S6, 4E-BP1-pS65, 4E-BP1, b-actin,
LRP6-pS1490, LRP6, TCF7L2, b-catenin, b-catenin-pS33/37/T41, IGF1R,
AKT-pT308, and Lamin B were purchased from Cell Signaling. Antibodies toetabolism 19, 209–220, February 4, 2014 ª2014 Elsevier Inc. 217
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Biotech. Antibodies to MTP, SREBP1, SREBP2, and IRS1 were purchased
from BD Biosciences. Antibodies to ACAT2 and IGF1 were purchased from
Novus. Antibodies to ELOVL6 (Thermo Scientific), DGAT1 (Bio Vision),
GPAT1 (GeneTex), LXRa (Abcam), HMGCR (Upstate), and IRS1-pY612 (Invi-
trogen) were used for western blotting.
Primary Hepatocyte Isolations
Primary hepatocytes were isolated by perfusing portal vein of 3-month-oldWT
and Lrp6mut/mutmalemice and 6-month-old Ldlr/miceand Ldlr//Lrp6mut/mut
male mice on indicated diets (n = 6) with collagenase (type II collagenase,
GIBCO). Isolated hepatocytes were Percoll purified and cultured on
collagen-coated tissue culture dishes in William’s medium supplemented
with primary hepatocytes maintenance supplements (GIBCO) and kept in a
humidified cell culture incubator at 37C and 5% CO2.
Generation of Stable LRP6 or Sp1 Knockdown Cells
For LRP6 knockdown in HepG2 cells, cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% heat-inactivated fetal
bovine plasma and 13 penicillin-streptomycin at 37C in a humidified
O2/CO2 (19:1) atmosphere. Lentivirus particles containing LRP6 targeting
shRNA (50-CGGCGAATTGAAAGCAGTGAT-30 ) were purchased (Santa Cruz
Biotech) and transduced into HepG2 cells. Transduced cells were selected
using 1 mg/mL puromycin.
For Sp1 knockdown, isolated primary hepatocytes were cultured on
collagen-coated tissue culture dishes in William’s medium supplemented
with primary hepatocytes maintenance supplements (GIBCO). Cells were
infected with Sp1 shRNA (m) lentiviral Particles (sc-29488-V, Santa Cruz
Biotech) using polybrene to increase the efficiency of infection.
Plasma and Liver Lipid Determination
Blood from fasted animals was obtained, and plasma was separated (1,500 g
for 15 min). Plasma TG, total C, and LDL C were analyzed at the Mouse Meta-
bolic Phenotyping Center at Yale by COBAS Mira Plus (Roche). Liver tissues
were homogenized in 5% NP-40 in water slowly heated to 95C for 5 min.
Collected supernatants after centrifugation (14,000 g for 10min) were assayed
for total hepatic C and TG content using colorimetric enzymatic kit (Wako).
Lipoprotein Profiling by Fast Protein Liquid Chromatography
Plasma lipoprotein profiling was determined by fast protein liquid chromatog-
raphy (FPLC). In brief, plasma from ten mice from each genetic background
was pooled for FPLC analysis. A total of 200 ml plasma was loaded and run
on the system followed by fractionation. Cholesterol levels of the fractions con-
taining the plasma lipoproteins were analyzed by standard enzymatic assays
using lipoprotein diagnostic kits (Wako).
Measurement of Hepatic Lipogenesis
Isolatedprimary hepatocytes ofWT, Lrp6mut/mut, Ldlr/, and Ldlr//Lrp6mut/mut
micewere serum starved overnight, followed by insulin stimulation (100 nM) for
4 hr. Insulin stimulated primary hepatocytes were incubated with 25.0 nmol of
[1,2-14C]-acetate (PerkinElmer), 12.5 nmol [1-14C]-plamitate (PerkinElmer),
and 12.5 nmol [1-14C]-oleate (PerkinElmer) for 2 hr. Cells were washed three
times with PBS before harvest in Cellstripper (Cellgro). Total lipid from cells
was prepared by the Bligh and Dyer method (Bligh and Dyer, 1959). Concen-
trated neutral lipids were dissolved in chloroform: methanol (2:1, v/v) and lipid
fractions were separated by TLC (Silica 60 F254, Merck) using the organic
mobile solvents hexane/diethylether/acetic acid (70:30:1 v/v). Lipids dots
were visualized under UV light, and radioactivity was determined using a scin-
tillation counter and normalized to protein concentrations.
Clearance of 125I-VLDL Particles
The rate of VLDL particle clearance from plasma was determined using
125I-labeled VLDL (Biomedical Technologies, Inc.). In brief, 3-month-old
chow-diet-fed WT and Lrp6mut/mut mice were fasted for 4 hr at the beginning
of light cycle to remove chylomicron. Mice were injected with 200 ml i.v. bolus
of 125I-VLDL (15 mg in 10 mM TrisCl [pH 7.4], 150 mM NaCl, and 0.2% [w/v]
BSA). Blood collection was performed at 2 (baseline), 30, 60, 120, and
240 min, and plasma was separated immediately. To separate VLDL fraction218 Cell Metabolism 19, 209–220, February 4, 2014 ª2014 Elsevier Infrom plasma, plasma in 750 ml KBr solution (d = 1.006 g/mL) was placed in
an ultracentrifuge (Thermo Scientific, NC) and spun at 90,000 rpm for 3 hr at
4C. The radioactivity of 125I-labeled VLDL in plasma at each time point was
determined by gamma counter after isopropanol precipitation of apoB. The
remaining amount of 125I-VLDL apoB was calculated as a percentage of the
initial concentration 2 min after injection.
Measurement of apoB Secretion In Vivo
The accumulation of 35S-methionine-labeled apoB in plasma was used to
determine VLDL production rate. Briefly, 3-month-old chow-diet-fed WT and
Lrp6mut/mut mice were fasted for 6 hr. The mice were anesthetized with 30%
isoflurane in propylene glycol, followed by i.p. injection of 200 ml bolus contain-
ing 200 mCi 35S-methionine and 1,000 mg/kg i.p. Poloxamer-407 (P407,
BASF), an inhibitor of lipoprotein lipase in sterile PBS. Blood samples were
collected at 30, 60, and 120 min after injection. Total protein synthesis after in-
jection was calculated by measuring radioactivity of TCA precipitable protein
in plasma. Adjusted volumes of plasma in sample buffer were applied to
SDS-PAGE gel and visualized by Coomassie blue staining (SimplyBlue,
Invitrogen) and scanned for densitometry.
TG Synthesis Using P407 Injection
To measure hepatic TG production, mice were injected with P407 at
1,000 mg/kg BW after 4 hr fasting. Plasma samples were collected at 0, 1,
2, 6, and 24 hr following injection. TG in plasma at each time point was
measured using an enzymatic kit (Wako). The TG production rates were
calculated from the differences in plasma TG levels over a given interval
following detergent injection.
Cholesterol and Cholesterol Ester Biosynthesis In Vitro
The cholesterol synthesis was determined by measuring the incorporation of
[1,2-14C]-acetate into cellular sterol. Isolated primary hepatocytes of Ldlr/
and Ldlr//Lrp6mut/mut mice were incubated with 25.0 nmol of [1,2-14C]-
acetate for 72 hr at 37C. [1,2-3H]-cholesterol was added to the aliquots as
an internal standard (0.04 mCi/sample), and the solutions were saponified us-
ing KOH in 100% ethanol (60C for 1 hr). Concentrated lipid aliquot resolved in
small volume of dichlromethane was applied to TLC (Silica gel 60, EMD), using
petroleum ether/diethyl ether/acetic acid (70:30:1). Cholesterol dots were
visualized with 1% ferric (III) chloride in 50% aqueous ethanol and were
scraped off for radioactivity determination.
Cholesterol ester synthesis was determined by incubating primary hepato-
cytes with [1-14C]-oleate for 4 hr, using same steps as described above.
Neutral lipid collection and TLC separation were performed as described
above. Cholesterol ester fractions were scraped off, and the radioactivity
was determined. Each condition was assayed in quadruples and normalized
to internal standard and protein concentrations in the original lysates.
In Vitro Assessment of b-Oxidation
The b-oxidation was assessed by trapping radioactive CO2 as described
elsewhere (Krieg et al., 2004). Briefly, isolated primary hepatocytes from
3-month-old WT and Lrp6mut/mut mice were incubated in vitro with 0.5 mCi
[1-14C]-palmitic acid in William’s medium for 2 hr. Culture flasks were tightly
attached to customized CO2 capture devices (Adams and Chittenden Scienti-
fic Glass). At the end of the 2 hr incubation period, reactionswere rapidly termi-
nated by addition of 5 N H2SO4, and cells were incubated for additional 30 min
to complete CO2 effervescence from the culture medium. The radioactivity of
the filter paper was determined.
Nile Red Staining
Isolated primary hepatocytes were cultured on collagen-coated glass cover-
slips. Cells were fixed with 4% paraformaldehyde in PBS and stained with
0.1 mg/mL Nile red for 30 min. Specimens were examined by Nikon Ti-E
Eclipse inverted microscope using excitation emission filters at 488 and
561 nm, respectively. Images were acquired at same setting of laser output,
gain, and offset for three independent experiment, and 20 cells were
randomly selected and analyzed from each coverslip. Similar experiment
was carried out after primary hepatocytes were treated with rmWnt3a for
72 hr.c.
Cell Metabolism
Wnt Regulation of Plasma LipidsFatty Acids Composition by Gas Chromatography
Lipid was extracted from liver tissues by the Folch method (Folch et al., 1957),
and fatty acids were saponified by KOH and methylated with boron fluoride-
methanol (BF3) in methanol (Morrison and Smith, 1964). Fatty acid methyl es-
ters were analyzed by gas chromatography (Varian model CP-3800 equipped
with a CP-8200 autosampler, Varian Inc.). Separation of fatty acid methyl
esters was accomplished on a fused silica capillary column (100 m 9
0.25 mm ID) (model CP-7420, Varian Inc.). An authentic standard (GLC
68-D, Nu-Chek Prep) was used to identify each peak.
Immunoblotting
Cytoplasmic and nuclear proteins were prepared using NE-PER nuclear and
cytoplasmic extraction kit (Thermo Scientific, #78833). Cell lysates were
processed and applied to SDS-PAGE and were immunoblotted using target
primary antibodies followed by appropriate HRP-conjugated secondary anti-
bodies. Enhanced chemiluminescence reagents were applied to develop the
blots, and blots were quantified with Bio-Rad Image Lab.
Quantitative RT-PCR
Total RNA was isolated from cultured cells using RNeasy Plus Mini Kit
(QIAGEN), and complementary DNA was synthesized from 5 mg of total RNA
primed with random hexamer and using Superscripts II reverse transcriptase.
Real-time PCR amplification was performed using specific primers (Tables S2
and S3) and iQ SYBRGreen Supermix (Bio-Rad). Reactions were performed in
quadruple with an 18S internal control. Relative quantification of mRNA levels
was expressed as fold increase relative to the control.
Intraperitoneal Insulin Tolerance Tests
Mice were fasted for 6 hr and i.p. injected with 0.75 U/kg insulin (Sigma). Blood
glucose and insulin levels were monitored from tail veins at 0, 15, 30, 45, 60,
and 120 min using a glucometer (OneTouch Ultra2, LifeScan). For the insulin
signaling experiment, mice were fasted for 6 hr and i.p. injected with
0.75 U/kg insulin. After 20 min, mice were sacrificed and tissues were snap
frozen for further analysis of immunoblotting.
Analysis of Liver Function and Histology
Six-month-old WT and Lrp6mut/mutmice fed HCD for 3 months were sacrificed
for microscopic analysis of lipid content and in vivo function test. Plasma was
prepared for biochemical analysis. Aspartate aminotransferase, alanine
aminotransferase, total bilirubin, albumin, and total protein were measured
by 7600-020 clinical analyzer (Hitachi). Liver tissues were embedded in
Tissue-Tek OCT cryostat molds (Leica) and frozen at 80C. These tissues
were used to generate 10-mm-thick sections in a cryostat. Tissue sections
were stained in 0.5% oil red O and counterstained with Mayer’s hematoxylin
or with hematoxylin and eosin for gross histological examinations.
Rapamycin, IGF1, and Wnta3a Treatment In Vitro
Isolated primary hepatocytes were cultured with 100 nM rapamycin for 12 hr
and stimulated with 1 mg/mL recombinant mouse IGF1 for 15 min. Whole-
cell lysates were analyzed by immunoblotting for the measurement of total
and phosphorylated proteins. For Wnt3a treatment, isolated primary hepato-
cytes were treated with 100 ng/mL recombinant mouse Wnt3a (rmWnt3a,
R&D Systems) for 12 hr, and the lysates were immunoblotted to examine pro-
tein and phosphoprotein expressions.
Intraperitoneal rmWnt3a Administration
Mice were injected with i.p. with 25 mg/kg rmWnt3a every other day for
3 weeks. Mice were sacrificed, and plasma was collected for lipid profiling
as described. Liver tissues were harvested for immunoblotting.
In Vitro Measurement of Fatty Acids Uptake
Isolatedprimary hepatocytes ofWT, Lrp6mut/mut, Ldlr/, and Ldlr//Lrp6mut/mut
micewere serum starved overnight, followed by insulin stimulation (100 nM) for
4 hr. Insulin-stimulated primary hepatocytes were incubated with 25.0 nmol of
[1,2-14C]-acetate, 12.5 nmol [1-14C]-palmitate, and 12.5 nmol [1-14C]-oleate
for 30 min. Uptake was terminated using ice-cold PBS supplemented with
2%BSA.Whole lysate was subjected to radioactivity counting. Each conditionCell Mwas assayed in quadruples, and protein concentration of parallel cultures was
measured using Bradford assay.
In Vitro Uptake of LDL and VLDL
Isolated primary hepatocytes of WT and Lrp6mut/mut mice were serum starved
overnight, followed by treatment with 125I-LDL or 125I-VLDL (Biomedical Tech-
nologies, Inc.). For binding assays, cells were prechilled at 4C followed by
adding 10 mg/mL 125I-LDL in DMEM supplemented with lipoprotein-deficient
serum for 2 hr at 4C. Cells were incubated with 2 ml of sodium dextran sulfate
(4 mg/mL, Sigma). An aliquot was placed in gamma counter to determine the
total amount of 125I-LDL bound to the cell surface. Cells were harvested, and
the lysate was used to measure protein concentration. For LDL or VLDL
uptake, cells were incubated in lipoprotein-deficient serum with 10 mg/mL
125I-LDL or 125I-VLDL for 2 hr at 37C. Harvested cell lysate was applied for
radioactivity determination as described previously.
VLDL1 and VLDL2 Separation
Large VLDL (VLDL1; S(f) = 60–400) and small VLDL (VLDL2; S(f) = 20–60) were
separated by ultracentrifugation density gradient technique after Lindgren,
Jensen, and Hatch as described previously (Al-Shayji et al., 2007). TG concen-
tration was then measured in each component with colorimetric enzymatic kit
(Wako).
IGF1 and IGF1R Inhibitor
Primary mice hepatocytes were cultured on collagen-coated tissue culture
dishes in William’s medium supplemented with primary hepatocytes mainte-
nance supplements (GIBCO). Cells were serum starved overnight before the
addition of 1 mM picropodophylin (PPP, Calbiochem) for 24 hr or/and
100 nM recombinant human IGF1 (R&D Systems) for 15 min or 24 hr. Whole-
cell lysates were analyzed by immunoblotting as described previously.
Statistical Analysis
All mice studies included seven mice in each group and were repeated at least
twice. All in vitro studies were carried out in quadruple. Comparisons between
two groups were performed using Student’s t test. For multiple comparisons,
LSD test in conjunction with ANOVAwas carried out. Data are mean ± SD, and
statistical significance is defined as p < 0.05.
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